Pentraxin 3 Detects Clinically Significant Fibrosis in Patients with Chronic Viral Hepatitis C
Pentraxin 3 (PTX3) plays a pathogenic role in experimental models of chronic liver injury and contributes to the progression of fibrosis. The detection of advanced fibrosis (METAVIR F≥3) is important to identify patients who are in urgent need of antiviral treatments versus those whose treatment cou...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2019-01-01
|
Series: | BioMed Research International |
Online Access: | http://dx.doi.org/10.1155/2019/2639248 |
id |
doaj-e8800acdb6804a41aa2d448a177a8f42 |
---|---|
record_format |
Article |
spelling |
doaj-e8800acdb6804a41aa2d448a177a8f422020-11-24T21:50:39ZengHindawi LimitedBioMed Research International2314-61332314-61412019-01-01201910.1155/2019/26392482639248Pentraxin 3 Detects Clinically Significant Fibrosis in Patients with Chronic Viral Hepatitis CJoanna Gorka-Dynysiewicz0Monika Pazgan-Simon1Jolanta Zuwala-Jagiello2Department of Pharmaceutical Biochemistry, Wroclaw Medical University, PolandDepartment of Infectious Diseases and Hepatology, Wroclaw Medical University, PolandDepartment of Pharmaceutical Biochemistry, Wroclaw Medical University, PolandPentraxin 3 (PTX3) plays a pathogenic role in experimental models of chronic liver injury and contributes to the progression of fibrosis. The detection of advanced fibrosis (METAVIR F≥3) is important to identify patients who are in urgent need of antiviral treatments versus those whose treatment could be deferred (F≥2). The aim was to assess the diagnostic value of PTX3 as a potential biomarker for clinically significant and advanced fibrosis. PTX3 associations with biochemical and histological parameters of inflammatory activity and fibrosis were investigated in 138 patients with chronic viral hepatitis C (HCV) before antiviral treatment. METAVIR histological scores of activity and fibrosis were obtained. PTX3 was measured by enzyme-linked immunosorbent assay. The diagnostic accuracy of serum PTX3 levels was compared to that of other fibrosis markers, including transforming growth factor‐β1 (TGF-β1), hyaluronic acid (HA), aspartate transaminase to platelet ratio index (APRI), fibrosis score based on four factors (FIB4), gamma-glutamyltranspeptidase to platelet ratio (GPR), and the liver stiffness measurement (LSM) by transient elastography (FibroScan®). In HCV patients the PTX3 level increased in parallel with the METAVIR histological score of activity, being independently associated with the METAVIR fibrosis score (P < 0.001). Using the receiver operating characteristics analysis, the best marker for detecting F≥2 and F≥3 was PTX3 with AUC = 0.802 and AUC = 0.867, respectively. The area under the curve of PTX3 for predicting significant fibrosis (F≥2) was significantly greater than those for the GPR ratio (AUC = 0.648) and FIB-4 score (AUC = 0.770) and similar to that for APRI index (AUC = 0.831). PTX3 provided clinically relevant diagnostic accuracy as a single marker of significant fibrosis.http://dx.doi.org/10.1155/2019/2639248 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Joanna Gorka-Dynysiewicz Monika Pazgan-Simon Jolanta Zuwala-Jagiello |
spellingShingle |
Joanna Gorka-Dynysiewicz Monika Pazgan-Simon Jolanta Zuwala-Jagiello Pentraxin 3 Detects Clinically Significant Fibrosis in Patients with Chronic Viral Hepatitis C BioMed Research International |
author_facet |
Joanna Gorka-Dynysiewicz Monika Pazgan-Simon Jolanta Zuwala-Jagiello |
author_sort |
Joanna Gorka-Dynysiewicz |
title |
Pentraxin 3 Detects Clinically Significant Fibrosis in Patients with Chronic Viral Hepatitis C |
title_short |
Pentraxin 3 Detects Clinically Significant Fibrosis in Patients with Chronic Viral Hepatitis C |
title_full |
Pentraxin 3 Detects Clinically Significant Fibrosis in Patients with Chronic Viral Hepatitis C |
title_fullStr |
Pentraxin 3 Detects Clinically Significant Fibrosis in Patients with Chronic Viral Hepatitis C |
title_full_unstemmed |
Pentraxin 3 Detects Clinically Significant Fibrosis in Patients with Chronic Viral Hepatitis C |
title_sort |
pentraxin 3 detects clinically significant fibrosis in patients with chronic viral hepatitis c |
publisher |
Hindawi Limited |
series |
BioMed Research International |
issn |
2314-6133 2314-6141 |
publishDate |
2019-01-01 |
description |
Pentraxin 3 (PTX3) plays a pathogenic role in experimental models of chronic liver injury and contributes to the progression of fibrosis. The detection of advanced fibrosis (METAVIR F≥3) is important to identify patients who are in urgent need of antiviral treatments versus those whose treatment could be deferred (F≥2). The aim was to assess the diagnostic value of PTX3 as a potential biomarker for clinically significant and advanced fibrosis. PTX3 associations with biochemical and histological parameters of inflammatory activity and fibrosis were investigated in 138 patients with chronic viral hepatitis C (HCV) before antiviral treatment. METAVIR histological scores of activity and fibrosis were obtained. PTX3 was measured by enzyme-linked immunosorbent assay. The diagnostic accuracy of serum PTX3 levels was compared to that of other fibrosis markers, including transforming growth factor‐β1 (TGF-β1), hyaluronic acid (HA), aspartate transaminase to platelet ratio index (APRI), fibrosis score based on four factors (FIB4), gamma-glutamyltranspeptidase to platelet ratio (GPR), and the liver stiffness measurement (LSM) by transient elastography (FibroScan®). In HCV patients the PTX3 level increased in parallel with the METAVIR histological score of activity, being independently associated with the METAVIR fibrosis score (P < 0.001). Using the receiver operating characteristics analysis, the best marker for detecting F≥2 and F≥3 was PTX3 with AUC = 0.802 and AUC = 0.867, respectively. The area under the curve of PTX3 for predicting significant fibrosis (F≥2) was significantly greater than those for the GPR ratio (AUC = 0.648) and FIB-4 score (AUC = 0.770) and similar to that for APRI index (AUC = 0.831). PTX3 provided clinically relevant diagnostic accuracy as a single marker of significant fibrosis. |
url |
http://dx.doi.org/10.1155/2019/2639248 |
work_keys_str_mv |
AT joannagorkadynysiewicz pentraxin3detectsclinicallysignificantfibrosisinpatientswithchronicviralhepatitisc AT monikapazgansimon pentraxin3detectsclinicallysignificantfibrosisinpatientswithchronicviralhepatitisc AT jolantazuwalajagiello pentraxin3detectsclinicallysignificantfibrosisinpatientswithchronicviralhepatitisc |
_version_ |
1725882477406322688 |